Acelyrin merges with Alumis in all-stock deal, transferring $448M cash and lonigutamab asset. Martin Babler to lead combined ...

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for ...

AstraZeneca on Thursday provided insight on an ongoing China probe into the company concerning alleged illegal drug imports, ...

B Health and two hospitals seek to intervene in Eli Lilly lawsuit, saying proposed rebate model would burden hospitals with ...

AstraZeneca cuts UK investment after government reduces site expansion support; Viking secures API supply; Jabil acquires ...

Eli Lilly reports 45% Q4 revenue jump to $13.53B, missing projections. Company maintains 2025 revenue outlook of $58-61B amid ...

Per­son­i­fy Health, which sells health­care spend­ing man­age­ment ser­vices to em­ploy­ers, has reached more than half a ...

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.

Bristol Myers Squibb announces $2B in new cost cuts over 3 years, including workforce reductions, following $1.5B cuts in ...

Progyny acquires BenefitBump and Teladoc buys Catapult Health for $65M, as digital health companies engage in dealmaking.